What new clinical studies are available for patients with metastatic differentiated thyroid carcinoma?

New Clinical Studies for Metastatic Differentiated Thyroid Cancer

For patients with progressive, RAI-refractory metastatic differentiated thyroid carcinoma requiring systemic therapy, lenvatinib remains the preferred first-line targeted therapy based on the most robust phase III evidence, while cabozantinib is now established as the preferred second-line option after prior systemic therapy failure. 1, 2

First-Line Systemic Therapy

Lenvatinib is the standard first-line kinase inhibitor for RAI-refractory DTC based on the SELECT trial, demonstrating:

• PFS gain of 14.7 months compared to placebo
• Hazard ratio of 0.21 (95% CI: 0.14-0.31) 1
• ESMO-MCBS score of 2 1
• Clinical benefit (response + stable disease) in 50-60% of patients for approximately 12-24 months 2

Important caveat: Lenvatinib carries >2% treatment-related mortality risk, requiring careful patient selection and monitoring 1.

Second-Line Systemic Therapy - Key Update

Cabozantinib has emerged as the preferred second-line option based on the COSMIC-311 trial for patients who have progressed during or after prior systemic therapy:

• PFS gain of 6.7 months versus placebo
• Hazard ratio of 0.22 (95% CI: 0.13-0.36) 1
• ESMO-MCBS score of 2 1

This represents a significant advance, as traditional cytotoxic chemotherapy (e.g., doxorubicin) has minimal efficacy and is not recommended 2.

Fusion-Driven Disease - Precision Medicine Approach

For the subset of patients with NTRK or RET fusion-positive metastatic DTC, highly selective targeted therapies are now available:

RET Fusion-Positive Disease

Two selective RET inhibitors show exceptional activity in previously treated patients:

• Selpercatinib (LIBRETTO-001):

  • ORR: 79%
  • Median PFS: 20.1 months
  • Median duration of response: 18.4 months
  • ESMO-MCBS score: 3 1

• Pralsetinib (ARROW):

  • ORR: 89%
  • Projected duration of response >9 months
  • ESMO-MCBS score: 3 1

Both agents are indicated for patients requiring systemic therapy following prior treatment with sorafenib and/or lenvatinib 1.

NTRK Fusion-Positive Disease

For the rare NTRK fusion-positive cases:

• Larotrectinib: ORR 79% (ESMO-MCBS score: 3) 1
• Entrectinib: ORR 57% (ESMO-MCBS score: 3) 1

Critical practice point: Genetic testing using allelic-specific real-time PCR or NGS should be performed to identify actionable fusions before initiating systemic therapy 1.

Emerging Molecular Insights from Recent Research

The 2026 genomic profiling study 3 reveals that distantly metastatic DTC is characterized by:

• Dysregulated phosphorylation signaling pathways (identified in 78% of cases)
• DNA damage repair (DDR) gene alterations in 13% of cases
• Novel actionable fusions including RFTN1::BRAF and SPON1::ALK
• DNMT3A mutations causing genome-wide methylation dysregulation

This suggests DDR gene-targeted therapy may represent a promising future strategy, though this remains investigational 3.

Prognostic Factors to Guide Treatment Intensity

Recent cohort studies identify key prognostic factors that should inform treatment decisions:

Poor Prognosis Indicators:

• Metachronous metastases (worse than synchronous; median PFS 95 months vs. not reached) 4
• Age ≥55 years at metastasis diagnosis 5, 6
• Multiple metastatic sites 6
• RAI-refractory disease (particularly with TERT promoter mutations) 5

Better Prognosis Indicators:

• Solitary brain metastases (though still poor overall) 7
• RAI-avid disease (64% disease control rate with RAI) 7
• Younger age at diagnosis 7, 6

Special Scenario: Brain Metastases

Brain metastases occur in <1% of DTC but carry significant morbidity. Recent 2026 data 7 shows:

• 66% demonstrate RAI-avidity
• Median OS only 15 months from brain metastasis diagnosis
• Three patients achieved complete remission with RAI, including two long-term survivors (>100 months)
• Disease control rate with RAI: 64%

Multimodal treatment (surgery, radiation, RAI when avid) is essential, though no single modality shows statistically significant survival advantage 7.

Treatment Algorithm

1. Confirm RAI-refractory status (progressive disease despite adequate RAI, or loss of iodine avidity)
2. Perform molecular profiling (NGS for RET/NTRK fusions, BRAF, TERT promoter mutations)
3. Assess need for systemic therapy (progressive or symptomatic disease only)
4. Treatment selection:
   • First-line: Lenvatinib (if no actionable fusion)
   • RET/NTRK fusion-positive: Consider selective inhibitors (selpercatinib, pralsetinib, larotrectinib, entrectinib)
   • Second-line after progression: Cabozantinib
5. Monitor closely for treatment-related toxicity and disease progression

Critical Pitfalls to Avoid

• Do not use traditional chemotherapy (doxorubicin) as it has minimal efficacy 2
• Do not initiate systemic therapy for stable, asymptomatic RAI-refractory disease - these agents have significant toxicity
• Do not skip molecular profiling - missing actionable fusions means missing superior treatment options
• Do not assume negative stimulated thyroglobulin excludes metastases - 4.67% of metastatic patients have negative sTg but positive post-therapeutic I-131 scans 8